Targeting the androgen signaling axis in prostate cancer
Activation of the androgen receptor (AR) and AR-driven transcriptional programs is central to
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …
the pathophysiology of prostate cancer. Despite successful translational efforts in targeting …
Super-enhancers complexes zoom in transcription in cancer
MT Wang, QY Chen, SJ Wang, H **e, J Liu… - Journal of Experimental …, 2023 - Springer
Super-enhancers (SEs) consist of multiple typical enhancers enriched at high density with
transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote …
transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote …
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells
Most prostate cancers express the androgen receptor (AR), and tumor growth and
progression are facilitated by exceptionally low levels of systemic or intratumorally produced …
progression are facilitated by exceptionally low levels of systemic or intratumorally produced …
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
MC Markowski, ME Taplin, R Aggarwal… - Nature …, 2024 - nature.com
Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a
treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer
How prostate cancer cells and their precursors mediate changes in the tumor
microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the …
microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the …
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer
M Mitsogianni, A Papatsoris, VM Bala… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Prostate cancer is the most common malignancy in the male. Androgen-
deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate …
deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate …
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
BACKGROUND Androgen receptor signaling inhibitors (ARSIs) have improved outcomes for
patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical …
patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical …
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM …
MD Nyquist, IM Coleman, JM Lucas, D Li, B Hanratty… - Cancer Research, 2023 - AACR
The androgen receptor (AR) pathway regulates key cell survival programs in prostate
epithelium. The AR represents a near-universal driver and therapeutic vulnerability in …
epithelium. The AR represents a near-universal driver and therapeutic vulnerability in …
Targeted therapy in salivary gland cancer: Prevalence of a selected panel of actionable molecular alterations in a German tertiary referral center patient cohort
Objective Salivary gland carcinomas (SGC) are a heterogeneous group of malignancies,
with 24 subtypes defined by the World Health Organization (WHO). The standard of therapy …
with 24 subtypes defined by the World Health Organization (WHO). The standard of therapy …
Bipolar androgen therapy: when excess fuel extinguishes the fire
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer
treatment. However, the progression towards castration-resistant prostate cancer is …
treatment. However, the progression towards castration-resistant prostate cancer is …